Geneva: Swiss pharmaceutical giant Novartis has received approval from the Japanese authorities for four drugs, including a medication for the treatment of leukaemia, the group said on Wednesday.
Leukaemia medication Tasigna, severe asthma medicine Xolair, high blood pressure drug Co-Dio and eye disease drug Lucentis can now be sold in Japan.
“It is a significant achievement to secure the approval of so many important new medicines for the benefit of Japanese patients in a single day,” said Joe Jimenez, chief executive officer of Novartis Pharma.
Tasigna, Xolair and Lucentis generated sales of $871 million (€677 million) in the first nine months of 2008.
The Basel-based group is scheduled to announce its full-year results next week.